Almirall (ALM.MC)

Executive Summary

Almirall is a global dermatology-focused pharmaceutical company headquartered in Barcelona, Spain, with a strong portfolio of approved products including tildrakizumab (Ilumetri) for plaque psoriasis and sarecycline (Seysara) for acne vulgaris. The company’s strategy centers on medical dermatology, and it maintains a direct commercial presence in Europe and the United States. Almirall’s pipeline includes several clinical-stage candidates, most notably LAD603 (a Phase 2 therapy for alopecia areata) which began recruitment in late 2025. The company also has a history of advancing dermatology treatments, with multiple completed Phase 3 trials in psoriasis and acne. Financially, Almirall is publicly traded (ALM.MC) with a market capitalization around €2.8 billion. Looking ahead, Almirall’s near-term growth will be driven by continued expansion of its dermatology franchise and progress in its pipeline. The key upcoming catalyst is the Phase 2 data readout for LAD603 in alopecia areata, a high unmet need area with significant commercial potential. Additionally, potential label expansions for existing products like tildrakizumab and new geographic launches could provide upside. However, the company faces competitive pressure in the dermatology space and reliance on a few key products. Overall, Almirall is well-positioned in dermatology with a manageable pipeline risk.

Upcoming Catalysts (preview)

• H2 2027LAD603 Phase 2 interim data readout for alopecia areata60% success
• 2026Potential FDA approval for new indication of tildrakizumab (e.g., pediatric psoriasis or psoriatic arthritis)50% success
• 2026Expansion of sarecycline into new geographic markets (e.g., European launches)70% success